Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.
Jeffrey A. Meyerhardt, MD, MPH, FASCO
Advertisement
Articles by Jeffrey A. Meyerhardt, MD, MPH, FASCO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 5/31
5